SEARCH

SEARCH BY CITATION

References

  • Applebaum PS, Roth LH, Lidz C. 1982. The therapeutic misconception: informed consent in psychiatric research. International Journal of Law and Psychiatry 5: 319329.
  • Dubois B, Feldman HH, Jacova C et al. 2007. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria Lancet Neurology 6: 734746.
  • Dubois B, Feldman HH, Jacova C et al. 2010. Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurology 9: 11181127.
  • Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. 2011. Alzheimer's disease Lancet 377: 10191031.
  • Callard F, Rose D, Wykes T. 2012. Close to the bench as well as at the bedside: involving service users in all phases of translational research. Health Expectations 15, 389400.
  • Corbett A, Pickett J, Burns A et al. 2012. Drug repositioning for Alzheimer's disease. Nature Reviews. Drug Discovery 11: 83346.
  • Carpenter B. D, Xiong C, Porensky E. K, et al. 2008. Reaction to a dementia diagnosis in individuals with Alzheimer's Disease and mild cognitive impairment. The American Geriatrics Society 56: 405412.
  • Donovan JL, Lane JA, Peters TJ, et al. 2009. Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. Journal of Clinical Epidemiology 62: 2936.
  • Emanuel EJ, Wendler D, Grady C. 2000. What makes clinical research ethical? Journal of the American Medical Association 283(20): 27012711.
  • Extance A. 2010. Alzheimer's failure raises questions about disease-modifying strategies. Nature Reviews. Drug Discovery 9: 749751.
  • Glaser B. 1978. Theoretical Sensitivity: Advances in the metholology of Grounded Theory. Calafornia: Sociology Press.
  • Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. 2006. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology 5(3): 228234.
  • Jack CR., Albert MS, Knopman DS, et al. 2011. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 7(3): 257262.
  • Karran E, Mercken M, Strooper B, 2011. D. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature Reviews. Drug Discovery 10: 698712.
  • Kim SYH, Cox C, Caine ED. 2002. Impaired decision-making ability in subjects with Alzheimer's disease and willingness to participate in research. The American Journal of Psychiatry 159: 797802.
  • Karlawish JHT., Casarett D, Klocinski J, Sankar P. 2001. How do AD patients and their caregivers decide whether to enroll in a clinical trial? Neurology 56: 789792.
  • Kitzinger J. 1995. Qualitative research: introducing focus groups British Medical Journal. 311: 299302.
  • McKhann GM, Knopman DS, Chertkow H, et al. 2011. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 7(3): 263269.
  • Mattsson N, Brax D, Zetterberg H. 2010. To know or not to know: ethical issues related to early diagnosis of Alzheimer's disease. International Journal of Alzheimer's Disease 2010: 14.
  • Ostrowitzki S, Deptula D, Thurfjell L, et al. 2012. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Archives of Neurology 69(2): 198207.
  • Petersen RC. 2009. Early diagnosis of Alzheimer's disease: is MCI too late? Currrent Alzheimer Research 6(4): 324330.
  • Prvulovic D, Hampel H. 2011. Ethical considerations of biomarker use in neurodegenerative diseases – a case study of Alzheimer's disease. Progress in Neurobiology 95(4): 517519.
  • Rinne JO, Brooks DJ, Rossor MN, et al. 2010. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurology 9(4): 363372.
  • Siemers ER, Friedrich S, Dean RA, et al. 2010. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clinical Neuropharmacology 33(2): 6773.
  • Singh I, Rose N. 2009. Biomarkers in psychiatry. Nature 460: 202207.
  • Sperling R, Jack C, Aisen P. 2011. Testing the right target and right drug at the right stage. Science Translation Medicine 3(111): 15.
  • Sperling R, Salloway S, Brooks DJ, et al. 2012. Amyloid-related imaging abnormalities in patients withAlzheimer's disease treated with bapineuzumab:a retrospective analysis. Lancet Neurology.
  • Williams MM, Scharff DP, Mathew KJ, et al. 2010. Barriers and facilitators of African American participation in Alzheimer Disease biomarker research. Alzheimer Disease and Association Disorders 24(3Suppl 1): S24S29.